Possible Reactivation of SARS-CoV-2 in a Patient with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Case Report.
Acute myeloid leukemia
Allogeneic hematopoietic stem cell transplantation
COVID-19
SARS-CoV-2
Journal
SN comprehensive clinical medicine
ISSN: 2523-8973
Titre abrégé: SN Compr Clin Med
Pays: Switzerland
ID NLM: 101740833
Informations de publication
Date de publication:
2021
2021
Historique:
accepted:
07
07
2021
pubmed:
27
7
2021
medline:
27
7
2021
entrez:
26
7
2021
Statut:
ppublish
Résumé
Reactivation or reinfection cases of SARS-CoV-2 are known but there is scarce evidence about reactivation in immunocompromised patients. Here, we report the case of a 61-year-old male undergoing a conditioning regimen with fludarabine, cyclophosphamide, and 2-Gy total body irradiation in preparation of a haplo-identical allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML). He received the first dose of a COVID-19 vaccine 6 weeks prior allo-HSCT and was hospitalized a month prior because of a COVID-19 bilateral pneumonia. On discharge, he showed two negative SARS-CoV-2 nasopharyngeal PCR swabs as well as a high SARS-CoV-2 antibody titer. On admission for allo-HSCT, he tested negative for SARS-CoV-2 again. Conditioning with fludarabine, cyclophosphamide, and 2-Gy total body irradiation was started and the patient developed lymphopenia. During his hospital stay, he tested positive for SARS-CoV-2 in a PCR test twice but remained asymptomatic. The conditioning regimen was continued as planned. Later during his stay, the patient showed undetectable SARS-CoV-2 load four times. This case documents possible reactivation of SARS-CoV-2 and raises questions about reactivation risks among recipients of stem cell transplants and other immunocompromised patients.
Identifiants
pubmed: 34308258
doi: 10.1007/s42399-021-01020-0
pii: 1020
pmc: PMC8294269
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2011-2015Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Conflict of InterestThe authors declare no competing interests.
Références
Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):13-25
pubmed: 33113040
J Infect. 2020 May;80(5):e14-e17
pubmed: 32171867
J Med Virol. 2021 Apr;93(4):2374-2384
pubmed: 33314153
J Infect Dis. 2017 Jul 15;216(2):203-209
pubmed: 28838146
Leukemia. 2021 Oct;35(10):2885-2894
pubmed: 34079042
Clin Microbiol Rev. 2019 Sep 11;32(4):
pubmed: 31511250
EBioMedicine. 2020 Sep;59:102960
pubmed: 32853988
Nature. 2020 Dec;588(7839):E35
pubmed: 33303961
Blood. 2010 Mar 11;115(10):2088-94
pubmed: 20042728
Biol Blood Marrow Transplant. 2014 Aug;20(8):1238-41
pubmed: 24732781
Front Med (Lausanne). 2020 Aug 20;7:531
pubmed: 32974374
J Hematol Oncol. 2020 Oct 2;13(1):131
pubmed: 33008453